LBF20407LX01: Difference between revisions
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
{{Metabolite | {{Metabolite | ||
|LipidBank= | |LipidBank=DFA8153 | ||
|LipidMaps=LMFA03040001 | |LipidMaps=LMFA03040001 | ||
|CAS=89663-86-5 | |CAS=89663-86-5 | ||
|SysName=(5S,6R,15S) -Trihydroxy- (trans-7,trans-9,cis-11,trans-13) - eicosatetraenoic acid | |SysName=(5S,6R,15S) -Trihydroxy- (trans-7,trans-9,cis-11,trans-13) - eicosatetraenoic acid | ||
|Common Name=&&Lipoxin A_4&&(5S,6R,15S) -Trihydroxy- (7E,9E,11Z,13E) -eicosatetraenoic acid&& | |Common Name=&&Lipoxin A_4&&(5S,6R,15S) -Trihydroxy- (7E,9E,11Z,13E) -eicosatetraenoic acid&& | ||
|UV Spectra= lambda max: 302nm epsilon : 50,000 | |UV Spectra=lambda max: 302nm epsilon : 50,000 | ||
|Source=LXA4 is formed in vitro by a number of mechanisms from arachidonic acid, 15-HpETE, and leukotriene A4 (LTA4 ) [[Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401|{{RelationTable/GetFirstAuthor|Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401}}]][[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335|{{RelationTable/GetFirstAuthor|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]]. | |Source=LXA4 is formed in vitro by a number of mechanisms from arachidonic acid, 15-HpETE, and leukotriene A4 (LTA4 ) [[Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401|{{RelationTable/GetFirstAuthor|Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401}}]][[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335|{{RelationTable/GetFirstAuthor|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]]. | ||
|Chemical Synthesis= | |Chemical Synthesis= |
Revision as of 05:51, 17 January 2014
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | DFA8153 |
LipidMaps | LMFA03040001 |
CAS | 89663-86-5 |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF20407LX01 |
Lipoxin A4 | |
---|---|
Structural Information | |
(5S,6R,15S) -Trihydroxy- (trans-7,trans-9,cis-11,trans-13) - eicosatetraenoic acid | |
| |
LXA4 | |
Formula | C20H32O5 |
Exact Mass | 352.224974134 |
Average Mass | 352.46508 |
SMILES | C(CCC(C=CC=CC=CC=CC(O)C(O)CCCC(O)=O)O)CC |
Physicochemical Information | |
LXA4 is formed in vitro by a number of mechanisms from arachidonic acid, 15-HpETE, and leukotriene A4 (LTA4 ) Edenius_C et al. Serhan_CN et al.. | |
LXA is equipotent to LTB in inducing superoxide generation in human neutrophils (0.1 mu M) Serhan_CN et al.. LXA4 is associated with several other biological functions including leukocyte activation, chemotaxis promotion, natural killer cell inhibition, and monocyte migration and adhesion Serhan_CN et al. Ramstedt_U et al. Maddox_JF et al.. | |
Spectral Information | |
Mass Spectra | |
UV Spectra | λ max: 302nm ε : 50,000 |
IR Spectra | |
NMR Spectra | |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|